pyrazines has been researched along with Thyroid Neoplasms in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 18 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, KY; Fagin, JA; Ghossein, R; Knauf, JA; Luckett, KA; Socci, ND; Voza, F | 1 |
| Ahn, BC; Baek, SH; Gangadaran, P; Hong, CM; Jeong, SY; Kalimuthu, SK; Lee, HW; Lee, J; Lee, SW; Li, XJ; Min, OJ; Rajendran, RL; Zhu, L | 1 |
| Eisner, F; Gerger, A; Pichler, M; Samonigg, H; Schaberl-Moser, R | 1 |
| Abramova, EB; Astakhova, TM; Bogomyagkova, YV; Choinzonov, EL; Erokhov, PA; Kondakova, IV; Kuznetsov, NA; Lyupina, YV; Plekhanova, AS; Rodoman, GV; Sharova, NP; Shashova, EE; Slonimskaya, EM; Sumedi, IR | 1 |
| El-Shentenawy, A; Mohammed, AA | 1 |
| Chiappetta, G; Di Maro, G; Jarzab, B; Masullo, M; Monaco, M; Oczko-Wojciechowska, M; Orlandella, FM; Salerno, P; Salvatore, G; Santoro, M; Thomas, G; Unger, K | 1 |
| Bhargava, R; Carty, SE; Chiosea, SI; Dabbs, D; Dacic, S; Dhir, R; Diaz, R; Ferris, RL; Gandhi, M; Kelly, LM; Kuan, SF; Lee, AV; Liu, P; Nikiforov, YE; Nikiforova, MN; Panebianco, F; Singhi, AD; Trivedi, S; Wald, AI; Wang, X; Zhong, S | 1 |
| Bauer, S; Bode, B; Knuth, A; Liewen, H; Renner, C; Samaras, P; Stenner, F; Tchinda, J; Weber, A; Zweifel, M | 1 |
| Brossart, P; Fröhlich, E; Wahl, R | 1 |
| Du, ZX; Guan, Y; Meng, X; Wang, HQ; Zhang, HY | 1 |
| Butler, PC; Elashoff, M; Elashoff, R; Gier, B; Matveyenko, AV | 1 |
| Du, ZX; Gao, YY; Liu, BQ; Meng, X; Niu, XF; Wang, HQ; Yan, Y; Zhang, HY | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Gundert-Remy, U; Spranger, J; Stammschulte, T | 1 |
| Arndt, T; Bartsch, DK; Brendel, C; Fischer, M; Greene, BH; Hinterseher, U; Hoffmann, S; Ramaswamy, A; Roth, S; Wunderlich, A | 1 |
| Niessen, M; Spinas, GA; Xu, L | 1 |
| Masmiquel Comas, L; Nicolau Ramis, J | 1 |
| Bartsch, DK; Brendel, C; Greene, BH; Hinterseher, U; Hoffmann, S; Ramaswamy, A; Roth, S; Wunderlich, A | 1 |
| Bale, RJ; Eisterer, W; Gabriel, M; Gastl, G; Kendler, D; Kroiss, A; Madleitner, R; Putzer, D; Uprimny, C; Virgolini, IJ | 1 |
| Altmann, A; Askoxylakis, V; Eisenhut, M; Haberkorn, U; Jesenofsky, R; Markert, A; Schöning, T | 1 |
| Akintayo, A; Chen, Z; El-Rayes, B; Fanucchi, MP; Harvey, RD; Kauh, JS; Khuri, FR; Lewis, CM; Nadella, P; Owonikoko, TK; Ramalingam, SS; Rogatko, A; Shin, DM; Tighiouart, M | 1 |
| Ain, KB; Fanourakis, G; Kotoula, V; McMillin, D; McMullan, C; Mitsiades, CS; Mitsiades, N; Negri, J; Poulaki, V; Tseleni-Balafouta, S | 1 |
| Adamo, L; Anastasi, G; Conticello, C; De Maria, R; Eramo, A; Giuffrida, D; Giuffrida, R; Gulisano, M; Iannolo, G; Memeo, L; Vicari, L; Zeuner, A | 1 |
| Delmore, JE; Hayden, P; Kotoula, V; McMillin, DW; McMullan, C; Mitsiades, CS; Mitsiades, N; Negri, J; Poulaki, V | 1 |
2 review(s) available for pyrazines and Thyroid Neoplasms
| Article | Year |
|---|---|
Advanced thyroid cancers: new era of treatment.
Topics: Anilides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; ErbB Receptors; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Lithium; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinazolines; Stilbenes; Thalidomide; Thyroid Neoplasms | 2014 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
2 trial(s) available for pyrazines and Thyroid Neoplasms
| Article | Year |
|---|---|
First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Quality of Life; Thyroid Neoplasms; Treatment Failure | 2012 |
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Pyrroles; Sunitinib; Thyroid Neoplasms | 2013 |
20 other study(ies) available for pyrazines and Thyroid Neoplasms
| Article | Year |
|---|---|
Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Cell Line, Tumor; Coumarins; Crizotinib; Disease Models, Animal; Drug Resistance, Neoplasm; Genes, p53; Humans; Indoles; MAP Kinase Signaling System; Mice; Mice, Transgenic; Mutation, Missense; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Pyrazines; Sulfonamides; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Triazoles | 2018 |
New Optical Imaging Reporter-labeled Anaplastic Thyroid Cancer-Derived Extracellular Vesicles as a Platform for In Vivo Tumor Targeting in a Mouse Model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; Extracellular Vesicles; Female; Genes, Reporter; Humans; Imidazoles; Luciferases, Renilla; Luminescent Agents; Mice; Mice, Nude; Optical Imaging; Pyrazines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
Topics: Adenocarcinoma, Follicular; Adult; Boronic Acids; Bortezomib; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazines; Sorafenib; Thyroid Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Changes in proteasome chymotrypsin-like activity during the development of human mammary and thyroid carcinomas.
Topics: Boronic Acids; Bortezomib; Breast; Breast Neoplasms; Chymotrypsin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Neoplasm Staging; Proteasome Endopeptidase Complex; Pyrazines; Thyroid Gland; Thyroid Neoplasms | 2013 |
Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Papillary; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Endoplasmic Reticulum Stress; Gene Knockdown Techniques; Humans; Mucoproteins; Neoplasm Invasiveness; Oncogene Proteins; Oxidation-Reduction; Protein Disulfide-Isomerases; Proteins; Pyrazines; Thyroid Cancer, Papillary; Thyroid Neoplasms; Up-Regulation | 2014 |
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Gene Expression Regulation, Neoplastic; Genetic Loci; Genome-Wide Association Study; Humans; Imidazoles; Insulin-Like Growth Factor II; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Oncogene Proteins, Fusion; Phosphatidylinositol 3-Kinases; Protein Biosynthesis; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Receptors, Somatomedin; RNA-Binding Proteins; RNA, Messenger; Signal Transduction; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyrazines; Pyridines; Sorafenib; Thyroid Neoplasms | 2008 |
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Carcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Iodides; Lovastatin; Neoplasm Metastasis; Oxides; Pyrazines; Sirolimus; Thymus Gland; Thyroid Neoplasms; Tretinoin | 2009 |
Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Adenosine Triphosphate; Apoptosis; Boronic Acids; Bortezomib; Catalytic Domain; Cell Line, Tumor; Flow Cytometry; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamate-Cysteine Ligase; Glutathione; Glutathione Synthase; Humans; Intracellular Space; Oxidative Stress; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Spectrophotometry; Thyroid Neoplasms | 2009 |
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Topics: Adverse Drug Reaction Reporting Systems; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Odds Ratio; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Thyroid Neoplasms; Triazoles; United States; United States Food and Drug Administration; Venoms | 2011 |
Proteasome inhibition induces a p38 MAPK pathway-dependent antiapoptotic program via Nrf2 in thyroid cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Glutamate-Cysteine Ligase; Glutathione; Humans; Microscopy, Confocal; NF-E2-Related Factor 2; p38 Mitogen-Activated Protein Kinases; Plasmids; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Small Interfering; Signal Transduction; Thyroid Neoplasms; Transcriptional Activation; Translocation, Genetic | 2011 |
GLP-1-based therapies: the dilemma of uncertainty.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Thyroid Neoplasms; Triazoles; Uncertainty; Venoms | 2011 |
Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
Topics: Adenocarcinoma, Follicular; Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Papillary; Caspase 3; Cell Cycle Checkpoints; Cell Proliferation; Flow Cytometry; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thyroid Neoplasms; Tumor Cells, Cultured | 2012 |
Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Thyroid Neoplasms; Triazoles; Venoms | 2011 |
[The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].
Topics: Animals; Breast Neoplasms; Calcitonin; Carcinoma, Medullary; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Disease Susceptibility; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Infections; Liraglutide; Pancreatitis; Pharmacovigilance; Pioglitazone; Pyrazines; Risk Assessment; Safety-Based Drug Withdrawals; Sitagliptin Phosphate; Species Specificity; Thiazolidinediones; Thyroid Neoplasms; Triazoles; Urinary Bladder Neoplasms | 2012 |
Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer.
Topics: Antineoplastic Agents; Aurora Kinases; Benzazepines; Boronic Acids; Bortezomib; Carcinoma; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; Indicators and Reagents; Protein Serine-Threonine Kinases; Pyrazines; Signal Transduction; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2012 |
Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mice; Mice, Inbred BALB C; Organ Specificity; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Medullary; Caspases; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Enzyme Inhibitors; Humans; Insulin-Like Growth Factor I; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins c-jun; Pyrazines; Thyroid Neoplasms; Tumor Suppressor Protein p53 | 2006 |
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Immunohistochemistry; Proteasome Inhibitors; Pyrazines; Retroviridae; Reverse Transcriptase Polymerase Chain Reaction; Thyroid Neoplasms; TNF-Related Apoptosis-Inducing Ligand | 2007 |
Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; BH3 Interacting Domain Death Agonist Protein; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Medullary; Cell Line, Tumor; Colorimetry; Doxorubicin; Genes, bcl-2; Humans; Membrane Potentials; Oncogene Protein v-akt; Protease Inhibitors; Pyrazines; RNA, Neoplasm; Tetrazolium Salts; Thiazoles; Thyroid Neoplasms; Transcription, Genetic | 2007 |